Blackrock Health Sciences Trust

49.15+0.3200+0.66%Vol 30.27K1Y Perf 20.79%
Apr 15th, 2021 15:59 DELAYED
BID48.25 ASK50.09
Open49.12 Previous Close48.83
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     66.98
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap- 
Earnings Rating
Price Range Ratio 52W %
85.48 
Earnings Date
-

Today's Price Range

49.0149.72

52W Range

38.6150.94

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
4.31%
1 Month
7.08%
3 Months
-0.89%
6 Months
11.73%
1 Year
20.79%
3 Years
40.67%
5 Years
33.71%
10 Years
169.28%

TickerPriceChg.Chg.%
BME49.150.32000.66
AAPL134.502.47001.87
GOOG2 296.6641.82001.85
MSFT259.503.91001.53
XOM56.98-0.3400-0.59
WFC42.240.25000.60
JNJ160.390.47000.29
FB307.825.00001.65
GE13.55-0.1300-0.95
JPM152.170.96000.63
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume30.27K
Shares Outstanding0
Trades Count278
Dollar Volume2.36M
Avg. Volume35.43K
Avg. Weekly Volume31.91K
Avg. Monthly Volume32.42K
Avg. Quarterly Volume35.50K

Blackrock Health Sciences Trust (NYSE: BME) stock closed at 49.15 per share at the end of the most recent trading day (a 0.66% change compared to the prior day closing price) with a volume of 30.27K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Asset Management industry, Financial Services sector and employs 0 people. Blackrock Health Sciences Trust CEO is John M. Perlowski.

The one-year performance of Blackrock Health Sciences Trust stock is 20.79%, while year-to-date (YTD) performance is 3.28%. BME stock has a five-year performance of 33.71%. Its 52-week range is between 38.61 and 50.94, which gives BME stock a 52-week price range ratio of 85.48%

Blackrock Health Sciences Trust currently has a PE ratio of 6.80, a price-to-book (PB) ratio of 1.02, a price-to-sale (PS) ratio of 7.08, a price to cashflow ratio of 181.80, a PEG ratio of 2.32, a ROA of 15.79%, a ROC of -% and a ROE of 16.03%. The company’s profit margin is 99.34%, its EBITDA margin is -%, and its revenue ttm is $80.09 Million , which makes it $6.70 revenue per share.

Of the last four earnings reports from Blackrock Health Sciences Trust, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Blackrock Health Sciences Trust’s next earnings report date is -.

The consensus rating of Wall Street analysts for Blackrock Health Sciences Trust is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Blackrock Health Sciences Trust stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blackrock Health Sciences Trust has a dividend yield of 5.06% with a dividend per share of $2.40 and a payout ratio of 47.00%.

Blackrock Health Sciences Trust has a Buy technical analysis rating based on Technical Indicators (ADX : 9.85, ATR14 : 1.33, CCI20 : 235.21, Chaikin Money Flow : 0.03, MACD : -0.08, Money Flow Index : 73.73, ROC : 6.80, RSI : 54.71, STOCH (14,3) : 88.13, STOCH RSI : 1.00, UO : 64.12, Williams %R : -11.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blackrock Health Sciences Trust in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Blackrock Health Sciences Trust

Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.

CEO: John M. Perlowski

Telephone: +1 800 882-0052

Address: 100 Bellevue Parkway, Wilmington 19809, DE, US

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

56%44%

News

Stocktwits